{"filing":{"accession_number":"0001193125-26-384339","cik":"0001830487","ticker":"PHVS","company_name":"Pharvaris N.V.","form":"6-K","filing_date":"2026-09-08","report_date":"2026-09-08","primary_document":"6-k_september_8_2026.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1830487/000119312526384339/6-k_september_8_2026.htm"},"events":[{"id":31750,"run_id":29152,"accession_number":"0001193125-26-384339","anchor_item_number":"EX-99.1","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.92,"summary":"This is a press release announcing positive topline results from the CHAPTER-3 pivotal Phase 3 clinical trial of deucrictibant XR for HAE prophylaxis. The disclosure reports that the primary endpoint was met with 83% attack rate reduction versus placebo (p\u003c0.0001), all secondary efficacy endpoints were met with statistical significance, and the drug demonstrated a well-tolerated safety profile. While technically a clinical trial result rather than financial earnings, this constitutes a material clinical milestone disclosure that would significantly affect investor assessment of the company's pipeline value and regulatory prospects, warranting classification as an earnings_release analog for a clinical-stage biotech company.","company_name":"Pharvaris N.V.","ticker":"PHVS","filing_date":"2026-09-08","form":"6-K","submitted_at":null,"items":[{"id":34727,"accession_number":"0001193125-26-384339","item_number":"EX-99.1","item_title":"phvs-ex99_1.htm","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.92,"reasoning":"This is a press release announcing positive topline results from the CHAPTER-3 pivotal Phase 3 clinical trial of deucrictibant XR for HAE prophylaxis. The disclosure reports that the primary endpoint was met with 83% attack rate reduction versus placebo (p\u003c0.0001), all secondary efficacy endpoints were met with statistical significance, and the drug demonstrated a well-tolerated safety profile. While technically a clinical trial result rather than financial earnings, this constitutes a material clinical milestone disclosure that would significantly affect investor assessment of the company's pipeline value and regulatory prospects, warranting classification as an earnings_release analog for a clinical-stage biotech company.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-09-08T10:52:44.457264+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":34727,"accession_number":"0001193125-26-384339","item_number":"EX-99.1","item_title":"phvs-ex99_1.htm","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.92,"reasoning":"This is a press release announcing positive topline results from the CHAPTER-3 pivotal Phase 3 clinical trial of deucrictibant XR for HAE prophylaxis. The disclosure reports that the primary endpoint was met with 83% attack rate reduction versus placebo (p\u003c0.0001), all secondary efficacy endpoints were met with statistical significance, and the drug demonstrated a well-tolerated safety profile. While technically a clinical trial result rather than financial earnings, this constitutes a material clinical milestone disclosure that would significantly affect investor assessment of the company's pipeline value and regulatory prospects, warranting classification as an earnings_release analog for a clinical-stage biotech company.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-09-08T10:52:44.457264+00:00","company_name":"Pharvaris N.V.","ticker":"PHVS","filing_date":"2026-09-08"}]}